<DOC>
	<DOCNO>NCT01218451</DOCNO>
	<brief_summary>The purpose study assess feasibility single prim dose NeisVac-C infant ( either 4 6 month age ) , determine immune response .</brief_summary>
	<brief_title>NeisVac-C Single Prime Study Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subject infant age 8 11 week time first vaccination Subject clinically healthy determine investigator 's clinical judgment collection medical history physical examination Subject born full term pregnancy ( &gt; = 37 week ) birth weight &gt; = 2 kg The parent ( ) legally authorize representative subject provide write consent participation The parent ( ) legally authorize representative subject ability understand comply requirement protocol The parent ( ) legally authorize representative subject available duration study The parent ( ) legally authorize representative subject agree keep subject diary Subject history severe allergic reaction anaphylaxis , know sensitivity allergy component vaccine Subject acute chronic infection require systemic therapy ( antibiotic antiviral ) prescribe treatment within 2 week prior first vaccination study Subject rash dermatologic condition may interfere injection site reaction rating Subject currently , history , significant cardiovascular , respiratory , hepatic , renal , metabolic , autoimmune , rheumatic , hematological , neurological , neurodevelopmental disorder Subject disease , currently undergo form treatment , undergoing form treatment within 30 day prior study entry , could expect influence immune response Subject receive blood product immunoglobulins within 60 day study entry Subject receive live vaccine within 4 week inactivate subunit vaccine within 2 week schedule first vaccination Subject previously vaccinate meningococcal C disease Subject know suspect immune dysfunction Subject functional surgical asplenia ( e.g . due pathologic hemoglobinopathy , leukemia , lymphoma , etc . ) Subject administer investigational drug within six week prior study entry concurrently participate clinical study include administration investigational product Subject his/her parent ( ) / legally authorize representative dependent relationship study investigator study team member ; dependent relationship include close relative ( i.e . child , partner/spouse , sibling ) well employee investigator site conducting study</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>11 Weeks</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>